Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

7.10USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.10
Open
$7.10
Day's High
$7.30
Day's Low
$6.90
Volume
28,343
Avg. Vol
20,735
52-wk High
$11.73
52-wk Low
$5.60

Latest Key Developments (Source: Significant Developments)

Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin
Tuesday, 28 Nov 2017 08:30am EST 

Nov 28 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS.  Full Article

Cidara reports qtrly ‍basic and diluted net loss per share $0.73​
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::Cidara provides corporate update and reports third quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.73​.Cidara Therapeutics Inc - qtrly ‍total operating expenses $12.2 million versus $12.3 million.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.  Full Article

T2 Biosystems, Cidara Therapeutics enter partnership for commercial placement of T2Dx instruments
Wednesday, 6 Sep 2017 11:05am EDT 

Sept 6 (Reuters) - T2 Biosystems::Co, Cidara Therapeutics entered into exclusive partnership for commercial placement of T2Dx instruments to support CD101 drug trials​.Program is designed to accelerate enrollment in Cidara's CD101 trials and to increase uptake of T2's products..  Full Article

Cidara Q2 net loss per share $0.99​
Wednesday, 9 Aug 2017 04:31pm EDT 

Aug 9 (Reuters) - Cidara Therapeutics Inc :Cidara provides corporate update and reports second quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.99​.  Full Article

Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7
Thursday, 13 Jul 2017 12:40pm EDT 

July 13 (Reuters) - Broadfin Capital LLC :Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing.  Full Article

Prosight Management LP reports 5.2 pct passive stake in Cidara Therapeutics - SEC filing
Friday, 16 Jun 2017 02:04pm EDT 

June 16 (Reuters) - Prosight Management LP ::Prosight Management LP reports a 5.2 percent passive stake in Cidara Therapeutics Inc as of June 7, 2017 - SEC filing.  Full Article

Cidara Therapeutics Q1 loss per share $0.80
Wednesday, 10 May 2017 06:14pm EDT 

May 10 (Reuters) - Cidara Therapeutics Inc ::Q1 loss per share $0.80.  Full Article

Cidara Therapeutics awarded $6.9 million grant from CARB-X
Thursday, 30 Mar 2017 12:00pm EDT 

Cidara Therapeutics Inc : Cidara Therapeutics awarded $6.9 million grant from carb-x to advance development of its first cloudbreaktm antibiotic immunotherapy . Under grant, CARB-X will provide up to $3.9 million in base funding and up to $3.0 million in additional funding through phase 1 .CARB-X funding to advance novel first-in-class bispecific immunotherapy to fight multi-drug resistant bacterial infections.  Full Article

Cidara Therapeutics qtrly net loss per share $0.88
Wednesday, 15 Mar 2017 05:11pm EDT 

Cidara Therapeutics Inc : Cidara therapeutics inc - qtrly basic and diluted net loss per share $0.88 .Cidara therapeutics inc - cash, cash equivalents and short-term investments totaled $104.6 million as of december 31, 2016 - sec filing.  Full Article

Cidara Therapeutics reports unfavorable results of Phase 2 radiant trial of CD101 topical in VVC
Tuesday, 21 Feb 2017 07:30am EST 

Cidara Therapeutics Inc : Cidara Therapeutics reports unfavorable results of Phase 2 radiant trial of CD101 topical in VVC . Cidara Therapeutics Inc - further development of CD101 topical for VVC to be discontinued . Cidara Therapeutics Inc says further development of CD101 topical for VVC to be discontinued . Cidara Therapeutics Inc - CD101 IV development program in Candidemia and invasive Candidiasis continuing and remains on track .Cidara Therapeutics Inc says CD101 gel and ointment were well-tolerated.  Full Article

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage: